

RESEARCH ARTICLE

# Cardiorespiratory fitness and cognition in persons at risk for Alzheimer's disease

Clayton J. Vesperman<sup>1</sup> | Rui Wang<sup>1,9,10</sup> | Stephanie A. Schultz<sup>1,7,8</sup> | Lena L. Law<sup>1</sup> |  
Ryan J. Dougherty<sup>1,4</sup> | Yue Ma<sup>1</sup> | Jennifer M. Oh<sup>1</sup> | Dorothy F. Edwards<sup>4</sup> |  
Catherine L. Gallagher<sup>1,5</sup> | Nathaniel A. Chin<sup>1</sup> | Sanjay Asthana<sup>1,2</sup> |  
Bruce P. Hermann<sup>1,5</sup> | Mark A. Sager<sup>1,3</sup> | Sterling C. Johnson<sup>1,2,3</sup> | Dane B. Cook<sup>4,6</sup> |  
Ozioma C. Okonkwo<sup>1,2,3</sup>

<sup>1</sup>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

<sup>2</sup>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA

<sup>3</sup>Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

<sup>4</sup>Department of Kinesiology, University of Wisconsin School of Education, Madison, Wisconsin, USA

<sup>5</sup>Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

<sup>6</sup>Research Service, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA

<sup>7</sup>Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

<sup>8</sup>Department of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA

<sup>9</sup>The Swedish School of Sport and Health Sciences, GIH, Stockholm, Sweden

<sup>10</sup>Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

## Correspondence

Ozioma C. Okonkwo, 600 Highland Avenue,  
Madison, WI 53792, USA.

E-mail: [ozioama@medicine.wisc.edu](mailto:ozioama@medicine.wisc.edu)

## Abstract

**Introduction:** This study examined the relationship between cardiorespiratory fitness (CRF) and longitudinal cognitive functioning in a cohort enriched with risk factors for Alzheimer's disease (AD).

**Methods:** A total of 155 enrollees in the Wisconsin Registry for Alzheimer's Prevention completed repeat comprehensive neuropsychological evaluations that assessed six cognitive domains. Peak oxygen consumption (VO<sub>2</sub>peak) was the primary measure of CRF. Random effects regression was used to investigate the effect of CRF on cognitive trajectories.

**Results:** Higher CRF was associated with slower decline in the cognitive domains of verbal learning and memory ( $P < .01$ ) and visual learning and memory ( $P < .042$ ). Secondary analyses indicated that these effects were stronger among men than women, and for noncarriers of the apolipoprotein E  $\epsilon 4$  allele.

**Discussion:** Higher CRF was associated with a slower rate of the decline in episodic memory that occurs as a natural consequence of aging in a cohort enriched with risk factors for AD.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

## KEYWORDS

aging, cognition, episodic memory, exercise test, humans, neuropsychological tests

## 1 | BACKGROUND

The aging of populations around the world has led to an increase in the prevalence of Alzheimer's disease (AD). In the United States alone, the number of people expected to have AD may reach 13.8 million by 2050.<sup>1</sup> This projection has led to an intensification of research aimed at investigating modifiable factors that may delay the onset of symptoms related to the progression of AD.

Cognition is known to decline with normal cognitive aging and even more so in those with AD.<sup>2-4</sup> Although decreases in performance across cognitive domains such as memory, processing speed, attention, language, executive function, and visuospatial ability have been observed in normal cognitive aging, these are not necessarily indicative of a neurodegenerative process.<sup>2,5,6</sup>

Whereas physical activity is any bodily movement that results in energy expenditure, cardiorespiratory fitness (CRF) is the ability of the circulatory and respiratory systems to supply oxygen to the musculoskeletal system during sustained physical activity, and has been found to be associated with cognitive benefits in older populations.<sup>7-12</sup> Lower CRF in older populations has also been associated with greater cognitive decline over time.<sup>11,13</sup> However, not all studies have come to the same conclusion. One review of studies involving aerobic activities aimed at improving CRF failed to find cognitive benefits in healthy older adults.<sup>14</sup> Others have shown that aerobic exercise interventions may indeed slow cognitive decline in individuals with AD.<sup>1</sup> This discrepancy between the potential benefits of CRF on cognition may become clearer with additional longitudinal research on cognitive change. With the expected rise in AD prevalence, strategies to alter the prospective course of cognitive change in those at risk for developing AD have become a critical focus for research. Further insights into early cognitive change may highlight points of intervention to slow the progression of AD-related cognitive decline.

When investigating the impact of CRF on cognition in a population at risk for AD, it is important to consider individual differences that may impact cognition and CRF. There is strong evidence that CRF differs between sexes, with males showing higher CRF on average.<sup>15,16</sup> Additionally, sex-dependent differences have been observed when investigating the linkage between CRF and cognition.<sup>8,17</sup> Although carriage of the apolipoprotein E (APOE)  $\epsilon$ 4 allele is associated with increased risk of cognitive impairment and decline,<sup>18</sup> this impact of APOE  $\epsilon$ 4 carriage has been shown to potentially be altered by behavioral choices.<sup>16</sup> Together, these present an opportunity to investigate how lifestyle strategies may differentially impact certain subpopulations.

Accordingly, the objective of this study was to investigate the impact of CRF on cognition over time, in a population with heightened risk for AD.<sup>19</sup> Peak oxygen consumption ( $VO_{2\text{peak}}$ , ml/kg/min), the "gold standard" for measuring CRF, was used as our fitness metric.<sup>12</sup> Consis-

tent with the principles of cognitive reserve and resistance to AD, we hypothesized that individuals with higher CRF would exhibit preserved cognitive function over time compared to their less fit peers.<sup>20,21</sup> As secondary analyses, we also investigated the extent to which our initial findings differed across strata defined by sex and carriage of the APOE  $\epsilon$ 4 allele.

## 2 | METHODS

### 2.1 | Participants

One hundred fifty-five participants enrolled in the Wisconsin Registry for Alzheimer's Prevention (WRAP) were included in this study. WRAP is a longitudinal, observational study established in 2001 and currently includes >1500 individuals who were cognitively normal and between the ages of 40 and 65 at study entry.<sup>19,22</sup> WRAP participants undergo their first follow-up visit 4 years after the baseline visit, with subsequent visits occurring every 2 years thereafter. All participants are diagnostically characterized in standardized, multidisciplinary, consensus conference wherein cognitive normalcy is determined on the basis of intact performance (typically above  $-1.5$  standard deviation [SD] normative thresholds) on a battery of cognitive tests, absence of neurologic/psychiatric conditions that might impair cognition as determined by a licensed clinician, and preserved functional abilities based on self or informant reports.<sup>22</sup> The WRAP cohort is enriched with risk factors for AD including family history of AD and/or APOE  $\epsilon$ 4 carriage. APOE  $\epsilon$ 4 genotype was determined using competitive polymerase chain reaction-based assays (LGC Genomics).<sup>22</sup> APOE  $\epsilon$ 4+ status was defined as carrying one or two copies of the  $\epsilon$ 4 allele.

Participants for this report were selected based on completion of repeated neuropsychological evaluation and a valid graded exercise test (GXT). All study procedures were approved by the University of Wisconsin Institutional Review Board and each participant provided informed consent prior to study participation.

### 2.2 | Graded exercise test

A continuous GXT was performed on a treadmill (Trackmaster TMX428CP, Full Vision Inc.), using a modified Balke protocol, to assess CRF after a 12-hour fast from nicotine caffeine, alcohol, and medication (prescription and over the counter).<sup>23</sup> Participants refrained from exercise on the day of the test. The GXT was administered by a certified exercise physiologist and supervised by a physician. During a short warm-up period at 0% incline, a quick, yet comfortable, walking speed was determined prior to exercise testing as a safety measure. For

### RESEARCH IN CONTEXT

- Systematic Review:** The authors reviewed current literature using commonly used databases (PubMed, etc.), publications, and print resources. This search indicated a dearth of information on cardiorespiratory fitness (CRF) and longitudinal cognitive change in cohorts at risk for Alzheimer's disease (AD). Relevant sources are discussed and cited.
- Interpretation:** Our findings contribute to the literature that suggests that efforts aimed at improving CRF may potentially be a point of intervention to promote cognitive health and potentially protect against future development of AD.
- Future Directions:** The article outlines limitations of the current study that may serve as the foundation for additional studies in the future. These include the need for a more diverse population, longitudinal measurements of CRF, and investigating possible early cognitive changes that may be incipiently altering lifestyle choices.

### HIGHLIGHTS

- Longitudinal evaluation of cognition.
- Higher cardiorespiratory (peak oxygen consumption) fitness slowed age-related cognitive decline.
- Cohort with heightened risk for Alzheimer's disease was examined.

those able to, a walking speed of 3.5 miles per hour was used throughout the test. Every 2 minutes, the treadmill incline was increased by 2.5% until the participant reached volitional exhaustion or the exercise physiologist stopped the test due to safety concerns. Continuous measurements of oxygen uptake ( $VO_2$ ), carbon dioxide production, minute ventilation (VE), work rate, and heart rate were obtained using a metabolic cart and two-way non-rebreathing valve (TrueOne® 2400; ParvoMedics). The metabolic cart was calibrated prior to each test using standard gases with known concentrations within a calibrated three-liter syringe. Heart rate was continuously measured through a twelve-channel electrocardiogram device (Schiller CS-200; Exercise Stress System) and rating of perceived exertion (RPE) was assessed during the last 30 seconds of each stage. After volitional exhaustion, treadmill speed was reduced to 2 miles per hour at 0% incline for a 3-minute cool down period. Given that WRAP is a longstanding study with rolling enrollment, and that GXT was implemented as part of an ancillary study, participants completed their GXT at different points in time in their WRAP participation, not necessarily at their baseline WRAP visit.

**TABLE 1** Cognitive factors and their component tests

Cognitive factor	Cognitive tests
Immediate memory	Rey Auditory Verbal Learning Test—trials 1 and 2 <sup>47</sup>
Verbal learning and memory	Rey Auditory Verbal Learning Test—trials 3–5, and delayed recall <sup>47</sup>
Speed and flexibility	Trails A time, Trails B time, number named for Stroop Color-Word <sup>48,49</sup>
Working memory	Digit span forward, digit span backward, and letter-number sequencing subsets of Wechsler Adult Intelligence Scale III <sup>50</sup>
Visual learning and memory	Brief visuospatial memory test—total learning and delayed recall <sup>51</sup>
Story recall	Logical memory test I (immediate recall) and II (delayed recall) <sup>52</sup>

Peak effort was determined using criteria set by the American College of Sports Medicine.<sup>12</sup> Specifically, peak effort was reached if the participant met two of the following criteria: respiratory exchange rate  $\geq 1.15$ , change in  $VO_2 < 200$  ml with an increase in work, RPE  $\geq 17$ , and achieving at least 90% of age-predicted maximal heart rate. CRF was indexed as the peak  $VO_2$  (i.e.,  $VO_{2peak}$ ) when criteria were met. These criteria were used to avoid potential age-driven relationships when volitional effort was not met.<sup>24</sup>

### 2.3 | Cognitive evaluation

At each WRAP visit, participants undergo a comprehensive battery of cognitive tests.<sup>22</sup> As described in prior publications from our group<sup>25–28</sup> factor analyses using promax rotation and maximum likelihood estimation<sup>29</sup> were used to reduce the set of cognitive measures to a smaller number of factors and obtain weights used to combine the measures within each factor. The six resulting weighted factor scores were then standardized ( $\sim N[0, 1]$ ) into z-scores, using means and standard deviations obtained from the whole baseline sample. The cognitive factors are presented in Table 1.

### 2.4 | Statistical analyses

Random effects regression was used to investigate whether CRF impacted cognitive performance across visits.<sup>30</sup> Random intercept and slope were used with an unstructured covariance structure. The implementation of random effects for the intercept and slope allowed for the fact that each person might have a different “starting point” and a different “rate of change” as is typically the case in longitudinal studies. The “fixed effects” in the model included time (in years since cognitive baseline),  $VO_{2peak}$ ,  $VO_{2peak} \times$  time interaction, and the following covariates: age, sex, education, beta blocker usage (usage slows down the heart, impacting the readings during the GXT), number of study visits (to adjust for potential practice effects), history of diabetes, and history of depression to account for individual differences in their effects.<sup>1</sup> Our primary term of interest was the  $VO_{2peak} \times$  time

**TABLE 2** Demographic characteristics (N = 155)

Characteristic	Value <sup>a</sup>
Age at baseline (years)	53.7 (6.3)
Female (%)	67.7
Education (years)	16.34 (2.16)
Family history of Alzheimer's disease (%)	69.7
APOE ε4 carriage (%)	37.4
Diabetes (%)	4.5
Depression (%)	28.4
Beta blocker usage (%)	4.5
Body mass index (kg/m <sup>2</sup> )	27.54 (5.36)
VO <sub>2</sub> peak, ml kg <sup>-1</sup> min <sup>-1</sup>	26.09 (6.36)
Number of study visits (median) (range)	5.00 (2-6)
Number of Individuals with 2/3/4/5/6 study visits	2/5/14/58/76
Years of follow-up	12.16 (2.39)

<sup>a</sup>Values indicate mean (SD), unless otherwise indicated.

Abbreviations: APOE, apolipoprotein E; SD, standard deviation; VO<sub>2</sub>peak, peak oxygen consumption.

interaction. A significant interaction would indicate that CRF impacts the rate of change in cognition over time. Last, as secondary analyses, we refitted our original model after stratifying the study sample by APOE ε4 status and sex to investigate the extent to which our findings differed between subgroups of interest.<sup>17,18,31</sup> All statistical tests were run in IBM SPSS version 26 and findings were considered significant at  $P < .05$ .

### 3 | RESULTS

#### 3.1 | Participant characteristics

Most participants had a family history of AD (69.7%) and slightly more than a third were APOE ε4 carriers (37.4%). The sample was 67.7% female, with mean age of  $53.7 \pm 6.3$ . Participants in this study have been enrolled in WRAP for between 4 and 16 years, with a mean of

12.16 years. The median number of visits attended was 5 (range, 2–6). Further demographic characteristics can be found in Table 2.

#### 3.2 | CRF and cognitive trajectories

As summarized in Table 3, a significant VO<sub>2</sub>peak x time interaction was detected in the cognitive domains of verbal learning and memory (B [standard error (SE)] = 0.0032 [0.0012],  $P < .01$ ) and visual learning and memory (B [SE] = 0.0028 [0.0014],  $P < .042$ ). To further investigate these findings, we divided the sample into tertiles based on their VO<sub>2</sub>peak. The mean (SD) VO<sub>2</sub>peak, in ml/kg/min, for the tertiles are as follows: low CRF = 19.89 (2.76), moderate CRF = 25.22 (1.41), high CRF = 33.29 (4.6). Table 4 and Figure 1A and B show the model-predicted longitudinal decline trajectories in each cognitive function for the CRF tertiles. Those with higher CRF had a slower annual decline in their test scores compared to those with lower CRF for both verbal learning and memory (–0.18, –0.16, –0.13 unit change per year for low, moderate, and high CRF, respectively) and visual learning and memory (–0.071, –0.055, –0.034 unit change per year for low, moderate, and high CRF, respectively). No significant CRF effect was found on the longitudinal change rate for the other cognitive domains (Table S1 in supporting information).

#### 3.3 | Secondary analyses

Table 5 displays the results from the stratified analyses. For the APOE ε4 stratification, the VO<sub>2</sub>peak x time interaction reached the prespecified 0.05 threshold within the APOE ε4– group for the verbal learning and memory domain ( $P = .043$ ). When stratifying by sex, the only significant VO<sub>2</sub>peak x time interaction was found among male participants for verbal learning and memory domain ( $P = .009$ ).

### 4 | DISCUSSION

In this study, we found that in a middle-aged cohort enriched with risk factors for AD, higher CRF was associated with a slower decline in

**TABLE 3** Association between CRF and prospective cognitive functioning

Effect	Time		VO <sub>2</sub> peak		Time x VO <sub>2</sub> peak		R <sup>2</sup> (%)
	B (SE)	P	B (SE)	P	B (SE)	P	
Immediate memory	–0.14 (0.083)	.088	–0.00034 (0.016)	.983	0.00028 (0.0017)	.871	0.2
Verbal learning and memory	–0.24 (0.063)	.001	–0.030 (0.013)	.021	0.0032 (0.0012)	.010	22.2
Speed and flexibility	–0.085 (0.058)	.147	0.0043 (0.013)	.737	0.0011 (0.0011)	.298	3.3
Working memory	0.012 (0.053)	.813	–0.0029 (0.016)	.855	–0.000006 (0.00093)	.995	0
Visual learning and memory	–0.13 (0.072)	.079	–0.030 (0.015)	.046	0.0028 (0.0014)	.042	15.3
Story recall	–0.078 (0.072)	.279	–0.0016 (0.015)	.917	0.00008 (0.00014)	.954	0

Abbreviations: CRF, cardiorespiratory fitness; SE, standard error VO<sub>2</sub>peak, peak oxygen consumption.

†In addition to time, VO<sub>2</sub>peak, and time x VO<sub>2</sub>peak, the models included the following covariates: age, sex, education, beta blocker usage, number of study visits, history of diabetes, and history of depression.

**TABLE 4** Model-predicted longitudinal decline trajectories in verbal and visual learning and memory at low, moderate, and high levels of CRF

Cognitive outcome	CRF level	Intercept (baseline scores)			Slope (rate of change per year)		
		B	SE	P	B	SE	P
Verbal learning and memory	Low	1.17	0.61	.057	-0.18	0.056	.002
	Moderate	1.00	0.60	.095	-0.16	0.055	.005
	High	0.76	0.59	.202	-0.13	0.057	.021
Visual learning and memory	Low	1.78	0.72	.015	-0.071	0.065	.272
	Moderate	1.61	0.71	.023	-0.055	0.064	.387
	High	1.38	0.70	.050	-0.034	0.066	.609

Abbreviations: CRF, cardiorespiratory fitness; SE, standard error; VO<sub>2</sub>peak, peak oxygen consumption.

†The table presents model-predicted longitudinal cognitive trajectories at low, moderate, and high tertile levels of VO<sub>2</sub>peak, respectively. The covariates included age, sex, education, beta blocker usage, number of study visits, history of diabetes, and history of depression.

cognition over time. This finding was specifically within the cognitive domains of verbal learning and memory and visual learning and memory. Given that increased physical activity is a key means of favorably altering CRF,<sup>32</sup> these findings help contribute to the literature that suggests that physical activity aimed at improving CRF may potentially be a point of intervention to delay symptoms common to AD.


Graphical exploration of our findings revealed that individuals with higher CRF exhibited a slower decrease in their test scores for the two significant cognitive domains of verbal and visual learning and memory (see Figure 1A,B). Specifically, the rate of change in both verbal learning and memory (low CRF = -0.18, moderate CRF = -0.16, high CRF = -0.13) and visual learning and memory (low CRF = -0.071, moderate CRF = -0.055, high CRF = -0.034), shows that more physically fit individuals saw a lower yearly decrease in cognitive performance. One interpretation of this finding may be that individuals with higher CRF may retain the ability to benefit from practice across repeated exposures, unlike their less fit peers. Previous studies have found evidence that absence of practice effects may be a possible marker of early cognitive changes.<sup>33,34</sup> In our study, we found that the number of repeat exposures to the testing occasion was a significant predictor of performance on both verbal learning and memory (B [SE] = 0.49 [0.14],  $P < .001$ ) and visual learning and memory (B [SE] = 0.32 [0.16],  $P = .044$ ). The observation that the low fit individuals had a faster decrease on these two cognitive domains therefore potentially indicates an absence of benefits from practice. However, given that we controlled for interindividual differences in repeat exposure in our analyses, it is possible that our findings are not fully explained by repeat exposure to the test material, but through alternative means in which CRF is involved. This conclusion is further supported by the fact that the CRF tertiles did not differ in number of study visits attended (mean number of visits = 5.35 for low CRF, 5.37 for moderate CRF, and 5.22 for high CRF).

Our results are consistent with previous studies that documented the benefits of higher CRF on cognitive outcomes.<sup>13,35-37</sup> For example, Barnes et al. found that in an older population (mean age of 69 years), higher CRF at baseline was associated with less cognitive decline over 6 years.<sup>13</sup> Zhu et al. found that CRF in young adulthood was predictive of cognitive function 25 years later.<sup>36</sup> Our sample was younger


than that of Barnes et al. but older than Zhu et al., and the cohort our participants were drawn from are selected for heightened risk of AD, based on family history and APOE  $\epsilon 4$  carriage, compared to the general population. Nonetheless our findings are in line with these prior works and underscore the beneficial role that CRF has with respect to clinically relevant cognitive outcomes. Our results are also consistent with our group's recent study that found WRAP participants with higher baseline CRF showed slower annual decline in total gray matter and cognitive function.<sup>37</sup> Interestingly, our findings are only limited to episodic memory, which is the earliest cognitive domain to be impacted by AD.<sup>1</sup> Perhaps longer periods of observation may be needed to witness changes in other cognitive domains.

In our stratified analyses further exploring the two significant cognitive factors, we found a significant VO<sub>2</sub>peak x time interaction on verbal learning and memory for APOE  $\epsilon 4$ - individuals, when stratifying by APOE  $\epsilon 4$  status. When stratifying by sex, men retained a significant interaction for verbal learning and memory. Specifically, among men, there was a heightened positive effect of having higher CRF on the rate of change for verbal learning and memory over time. These findings suggest that there may be potentially different effects of CRF on longitudinal cognition between the sexes and based on carriage of the APOE  $\epsilon 4$  allele.<sup>16,37</sup> That said, it should be noted that the APOE  $\epsilon 4$ - group was about twice the size of the APOE  $\epsilon 4$ + group, which may have played a role in the differential APOE  $\epsilon 4$  effect. Further studies are necessary for more fully understanding these preliminary findings.

Some potential mechanisms behind our findings may involve improved cerebrovascular health. Higher CRF is associated with many cerebrovascular benefits including improved arterial compliance, cerebral blood flow, and white matter integrity.<sup>38-42</sup> Additionally, arterial stiffness has been found to be associated with faster cognitive decline and risk of developing dementia in older populations.<sup>43</sup> Vascular risk factors, such as hypertension and diabetes, also contribute to the structure and integrity of the brain itself, potentially impacting cognition.<sup>44,45</sup> Together, these suggest a cascade through which efforts to improve CRF may enhance vascular health and ultimately confer cognitive benefits. Future research in a larger cohort with a broader array of vascular abnormalities is needed to test this potential linkage through formal mediation analyses.



**CRF=Cardiorespiratory fitness**



**CRF=Cardiorespiratory fitness**

**FIGURE 1** A and B, Higher aerobic fitness was associated with slower decline in prospective memory functioning

**TABLE 5** Sex- and APOE  $\epsilon$ 4-stratified examination of the association between CRF and prospective episodic memory

Effect	Time		VO <sub>2</sub> peak		Time x VO <sub>2</sub> peak		R <sup>2</sup> (%)
	B (SE)	P	B (SE)	P	B (SE)	P	
Verbal learning and memory (male)	-0.40 (0.11)	.001	-0.070 (0.022)	.003	0.0058 (0.0021)	.009	—§
Verbal learning and memory (female)	-0.18 (0.079)	.024	-0.009 (0.018)	.606	0.0022 (0.0017)	.205	8.02
Visual learning and memory (male)	-0.11 (0.14)	.448	-0.030 (0.027)	.286	0.0023 (0.0028)	.41	13.2
Visual learning and memory (female)	-0.13 (0.086)	.121	-0.024 (0.019)	.197	0.0025 (0.0017)	.154	22.3
Verbal learning and memory (APOE $\epsilon$ 4+)	-0.25 (0.096)	.01	-0.038 (0.018)	.041	0.0031 (0.0018)	.093	16.4
Verbal learning and memory (APOE $\epsilon$ 4-)	-0.23 (0.085)	.007	-0.029 (0.019)	.127	0.0035 (0.0017)	.043	35.4
Visual learning and memory (APOE $\epsilon$ 4+)	-0.26 (0.12)	.028	-0.020 (0.019)	.304	0.0014 (0.002)	.491	36.9
Visual learning and memory (APOE $\epsilon$ 4-)	-0.045 (0.097)	.641	-0.036 (0.021)	.088	0.0036 (0.0019)	.071	10.5

Abbreviations: APOE, apolipoprotein E4; CRF, cardiorespiratory fitness; SE, standard error; VO<sub>2</sub>peak, peak oxygen consumption.

†In addition to time, VO<sub>2</sub>peak, and time x VO<sub>2</sub>peak, the models included the following covariates: age, sex, education, beta blocker usage, number of study visits, history of diabetes, and history of depression. Following Singer and Willett,<sup>30</sup> R<sup>2</sup> was calculated as the proportional reduction in the estimated variance of the random slope (i.e., change rate over time) between the models with versus without the time x VO<sub>2</sub>peak interaction term. It indicates the percentage of variance in the change rate explained by the interaction.

‡For verbal learning and memory (male), the variance estimate of the random slope was zero, and thus random intercept model was instead selected as the final model. Correspondingly, R<sup>2</sup> was not calculated.

Our study is not without limitations. Chiefly, the WRAP cohort is largely composed of highly educated, non-Hispanic White individuals harboring specific risk factors for AD; therefore, there is a potential restriction of the generalizability of our results to the larger population. Selection criteria also limits generalizability of the results as only those who were physically able to complete the GXT were included in analyses. Second, the more formal approach to testing sex and APOE  $\epsilon$ 4 differences on the effects of CRF on cognitive changes would entail fitting three-way interactions (e.g., sex x VO<sub>2</sub>peak x time), which would have been underpowered given the study sample size. Therefore, we instead performed stratified analyses, which are a statistically acceptable workaround.<sup>46</sup> However, stratified analysis might not completely resolve the power issue, given only part of the sample is included in the analysis at any point. Future research with increased sample sizes would be needed for thoroughly evaluating the sex and APOE differences. Also, our CRF measure was from one point in time and may not necessarily represent CRF over the entire duration of observation. Therefore, it would be of interest to collect repeat measurements of CRF to help shed light on whether, and to what extent, changes in CRF track with changes in cognition. In addition, given the number of cognitive measures tested, our analyses are potentially vulnerable to Type I error. Applying a conventional Bonferroni correction would set alpha at 0.008, rendering all associations nonsignificant. Such a correction was deemed overly restrictive but, that said, our findings should be interpreted cautiously. In addition, it is plausible that the cognitive domains not found to have significant VO<sub>2</sub>peak x time interactions simply had lesser variability over time in our sample compared to the domains of visual and verbal memory, suggesting possible psychometric limitations within our sample. Last, it is important to acknowledge the alternative possibility that the individuals with low CRF may already be experiencing the sequelae of incipient cognitive decline. In other words, rather than low CRF being the driver of poorer cognition, it is possible that awareness of very subtle cognitive changes might lead

some individuals to gradually refrain from certain lifestyle behaviors (such as physical activity) that are beneficial for CRF and cognition.

## 5 | CONCLUSION

We found that in a middle-aged cohort enriched with risk factors for AD, higher CRF was associated with slower decline in cognitive performance in the domain of episodic memory. These findings contribute to the literature that suggests that efforts aimed at improving CRF may potentially be a point of intervention to promote cognitive health and potentially protect against future development of AD.

## ACKNOWLEDGMENTS

Special thanks to the researchers, staff, and participants of the Wisconsin Registry for Alzheimer's Prevention for their continued dedication. This work was supported by National Institute on Aging grants R01 AG062167 (OCO), R21 AG051858 (OCO), and R01 AG027161 (SCJ); and by grant funding from the Extendicare Foundation and the Alzheimer's Association. Portions of this research were supported by the Veterans Administration including facilities and resources at the Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. Ryan J. Dougherty was supported by a National Research Service Award from the National Institute on Aging of the National Institutes of Health under Award Number F31AG062009.

## CONFLICTS OF INTEREST

The authors report no conflicts of interest.

## REFERENCES

1. Alzheimer's Association., 2019 Alzheimer's disease facts and figures. *Alzheimers Dementia*, 2019;15(3):321-387.

2. Harada CN, Natelson Love MC, Triebel KL. Normal Cognitive Aging. *Clin Geriatr Med*. 2013;29(4):737-752.
3. Vandenberghe R. Cognitive aging and Alzheimer's disease. *Postgrad Med J*. 2005;81(956):343-352.
4. Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizez LP, Bennett DA. The natural history of cognitive decline in Alzheimer's disease. *Psychol Aging*. 2012;27(4):1008-1017.
5. Glisky EL. Changes in cognitive function in human aging. In: Riddle DR, ed. *Brain Aging: Models, Methods, and Mechanisms*. Boca Raton (FL): CRC Press/Taylor & Francis; 2007.
6. Hoogendam YY, Hofman A, Van Der Geest JN, Van Der Lugt A, Ikram MA. Patterns of cognitive function in aging: the Rotterdam Study. *Eur J Epidemiol*. 2014;29(2):133-140.
7. Boots EA, Schultz SA, Oh JM, et al. Cardiorespiratory fitness is associated with brain structure, cognition, and mood in a middle-aged cohort at risk for Alzheimer's disease. *Brain Imaging Behav*. 2015;9(3):639-649.
8. Dougherty RJ, Schultz SA, Boots EA, et al. Relationships between cardiorespiratory fitness, hippocampal volume, and episodic memory in a population at risk for Alzheimer's disease. *Brain Behav*. 2017;7(3):e00625.
9. Okonkwo OC, Schultz SA, Oh JM, et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. *Neurology*. 2014;83(19):1753-1760.
10. Prakash RS, Voss MW, Erickson KI, et al. Cardiorespiratory fitness and attentional control in the aging brain. *Front Hum Neurosci*. 2011;4:229.
11. Wendell CR, Gunstad J, Waldstein SR, Wright JG, Ferrucci L, Zonderman AB. Cardiorespiratory fitness and accelerated cognitive decline with aging. *J Gerontol A Biol Sci Med Sci*. 2014;69(4):455-462.
12. American College of Sports Medicine. *ACSM's Guidelines for Exercise Testing and Prescription*. 9th ed. Wolters Kluwer/Lippincott Williams & Wilkins Health. 2014.
13. Barnes DE, Yaffe K, Satariano WA, Tager IB. A longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults. *J Am Geriatr Soc*. 2003;51(4):459-465.
14. Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. *Cochrane Database Syst Rev*. 2015;(4):CD005381.
15. Wang C-Y, Haskell WL, Farrell SW, et al. Cardiorespiratory fitness levels among US adults 20-49 years of age: findings from the 1999-2004 National Health and Nutrition Examination Survey. *Am J Epidemiol*. 2010;171(4):426-435.
16. Morris JK, Zhang G, Dougherty RJ, et al. Collective effects of age, sex, genotype, and cognitive status on fitness outcomes. *Alzheimers Dement (Amst)*. 2020;12(1):e12058.
17. Dimech CJ, Anderson JAE, Lockrow AW, Spreng RN, Turner GR. Sex differences in the relationship between cardiorespiratory fitness and brain function in older adulthood. *J Appl Physiol (1985)*. 2019;126(4):1032-1041.
18. Evans S, Dowell NG, Tabet N, Tofts PS, King SL, Rusted JM. Cognitive and neural signatures of the APOE E4 allele in mid-aged adults. *Neurobiol Aging*. 2014;35(7):1615-1623.
19. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. *J Geriatr Psychiatry Neurol*. 2005;18(4):245-249.
20. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. *Neurology*. 2018;90(15):695-703.
21. Okonkwo OC, Vemuri P. Stemming the Alzheimer tsunami: introduction to the special issue on reserve and resilience in Alzheimer's disease. *Brain Imaging Behav*. 2017;11(2):301-303.
22. Johnson SC, Kosciak RL, Jonaitis EM, et al. The Wisconsin Registry for Alzheimer's prevention: a review of findings and current directions. *Alzheimers Dement (Amst)*. 2018;10:130-142.
23. Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. *US Armed Forces Med J*. 1959;10(6):675-688.
24. Dougherty RJ, Lindheimer JB, Stegner AJ, Van Riper S, Okonkwo OC, Cook DB. An objective method to accurately measure cardiorespiratory fitness in older adults who cannot satisfy widely used oxygen consumption criteria. *J Alzheimers Dis*. 2018;61(2):601-611.
25. Dowling NM, Hermann B, La Rue A, Sager MA. Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. *Neuropsychology*. 2010;24(6):742-756.
26. Jonaitis EM, Kosciak RL, Clark LR, et al. Measuring longitudinal cognition: individual tests versus composites. *Alzheimers Dement (Amst)*. 2019;11:74-84.
27. Jonaitis EM, Kosciak RL, La Rue A, Johnson SC, Hermann BP, Sager MA. Aging, practice effects, and genetic risk in the Wisconsin Registry for Alzheimer's prevention. *Clin Neuropsychol*. 2015;29(4):426-441.
28. Kosciak RL, La Rue A, Jonaitis EM, et al. Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer's prevention. *Dement Geriatr Cogn Disord*. 2014;38(1-2):16-30.
29. Grice JW. A comparison of factor scores under conditions of factor obliquity. *Psychol Methods*. 2001;6(1):67-83.
30. Singer JD, Willett JB. *Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence*. Oxford University Press; 2003. 103 pg.
31. O'donoghue MC, Murphy SE, Zamboni G, Nobre AC, Mackay CE. APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: a review. *Cortex*. 2018;104:103-123.
32. Blair SN. Physical fitness and all-cause mortality. A prospective study of healthy men and women. *JAMA*. 1989;262(17):2395-2401.
33. Duff K, Beglinger L, Schultz S, et al. Practice effects in the prediction of long-term cognitive outcome in three patient samples: a novel prognostic index. *Arch Clin Neuropsychol*. 2007;22(1):15-24.
34. Duff K, Lyketsos CG, Beglinger LJ, et al. Practice effects predict cognitive outcome in amnesic mild cognitive impairment. *Am J Geriatr Psychiatry*. 2011;19(11):932-939.
35. Brown AD, Mcmorris CA, Longman RS, et al. Effects of cardiorespiratory fitness and cerebral blood flow on cognitive outcomes in older women. *Neurobiol Aging*. 2010;31(12):2047-2057.
36. Zhu N, Jacobs DR, Schreiner PJ, et al. Cardiorespiratory fitness and cognitive function in middle age: the CARDIA study. *Neurology*. 2014;82(15):1339-1346.
37. Dougherty RJ, et al. Cardiorespiratory fitness mitigates brain atrophy and cognitive decline in adults at risk for Alzheimer's disease. *Alzheimers Dement (Amst)*. 2021;13(1):e12212.
38. Gauthier CJ, Lefort M, Mekary S, et al. Hearts and minds: linking vascular rigidity and aerobic fitness with cognitive aging. *Neurobiol Aging*. 2015;36(1):304-314.
39. Johnson NF, Gold BT, Bailey AL, et al. Cardiorespiratory fitness modifies the relationship between myocardial function and cerebral blood flow in older adults. *Neuroimage*. 2016;131:126-132.
40. Wolters FJ, Zonneveld HI, Hofman A, et al. Cerebral perfusion and the risk of dementia: a population-based study. *Circulation*. 2017;136(8):719-728.
41. Kawano H, Yamamoto K, Gando Y, et al. Lack of age-related increase in carotid artery wall viscosity in cardiorespiratory fit men. *J Hypertens*. 2013;31(12):2370-2379.
42. Vesperman CJ, Pozorski V, Dougherty RJ, et al. Cardiorespiratory fitness attenuates age-associated aggregation of white matter hyperintensities in an at-risk cohort. *Alzheimers Res Ther*. 2018;10(1):97.
43. Pase MP, Herbert A, Grima NA, Pipingas A, O'rouke MF. Arterial stiffness as a cause of cognitive decline and dementia: a systematic review and meta-analysis. *Intern Med J*. 2012;42(7):808-815.
44. Dobbie S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. *Neurology*. 2011;77(5):461-468.



45. Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and cognitive impairment. *Curr Diab Rep*. 2016;16(9):87.
46. Behrens G, Winkler TW, Gorski M, Leitzmann MF, Heid IM. To stratify or not to stratify: power considerations for population-based genome-wide association studies of quantitative traits. *Genet Epidemiol*. 2011;35(8):867-879.
47. Schmidt M. *Rey Auditory Verbal Learning Test: A Handbook*. Western Psychological Services; 1996.
48. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. *Percept Mot Skills*. 1958;(8):271-276.
49. Trenerry B. *The Stroop Neuropsychological Screening Test*. Psychological Assessment Resources, Inc; 1989.
50. Wechsler D. *Wechsler Adult Intelligence Scale - III*. San Antonio, TX: The Psychological Corporation; 1997.
51. Benedict R. *Brief Visuospatial Memory Test - Revised*. Psychological Assessment Resources, Inc; 1997.
52. Wechsler D. *Wechsler Memory Scale - Revised*. Harcourt Brace Jovanovich, Inc. for the Psychological Corporation; 1987.

### SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Vesperman CJ, Wang R, Schultz SA, et al. Cardiorespiratory fitness and cognition in persons at risk for Alzheimer's disease. *Alzheimer's Dement*. 2022;14:e12330. <https://doi.org/10.1002/dad2.12330>